Kyntra Bio, Inc.
USUSDKyntra Bio, Inc. (LSE:0IL8) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 2. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- kyntrabio.com
- Investorite Suhted
- investor.kyntrabio.com/
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Peakontor
- SAN FRANCISCO, United States
- Tegevjuht
- Thane Wettig
- Töötajad
- 34
- Börsil Alates
- 29.01.2018 (LSE:0IL8)
- Ringluses Olevad Aktsiad
- Vabalt Kaubeldavad Aktsiad
- 3.57 mln
- Turukapitalisatsioon
- 24.74 mln USD
- Siseringi Isikud
- 2.02%
- Institutsionaalsed Investorid
- 24.68%
- Tegevusala (SIC)
- Pharmaceutical Preparations
- P/E
- kahjum
- FCF
- −38.1 mln USD
- Võlg
- 75.0 mln USD
- Kasum ja FCF — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
Kirjeldus
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| Armistice Capital, LLC | 9.88% | 400 000 | 2026-06-30 |
| CHUNG CHRISTINE (Officer… | ≈7.28% | 294 903 | 2025-03-06 |
| Vanguard Capital Managem… | 3.95% | 159 950 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.82% | 114 179 | 2026-06-30 |
| Acadian Asset Management… | 2.61% | 105 585 | 2026-06-30 |
| Blackrock Inc. | 2.08% | 84 330 | 2026-06-30 |
| Geode Capital Management… | 1.07% | 43 219 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.04% | 42 265 | 2026-06-30 |
| HighTower Advisors, LLC | 0.98% | 39 746 | 2026-06-30 |
| Two Sigma Investments, L… | 0.98% | 39 511 | 2026-06-30 |
| WETTIG THANE (Chief Exec… | ≈0.67% | 27 243 | 2026-05-14 |
| Renaissance Technologies… | 0.67% | 27 081 | 2026-06-30 |
| Vanguard Fiduciary Trust… | 0.6% | 24 105 | 2026-06-30 |
| Birchview Capital, LP | 0.56% | 22 566 | 2026-06-30 |
| Fidelity Concord Street… | 0.47% | 19 022 | 2026-07-31 |
| Fidelity Concord Street… | 0.17% | 7 005 | 2026-07-31 |
| Fidelity Concord Street… | 0.14% | 5 744 | 2026-07-31 |
| VANGUARD VALLEY FORGE FU… | 0.09% | 3 506 | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.07% | 2 716 | 2026-06-30 |
| Fidelity Concord Street… | 0.05% | 1 991 | 2026-07-31 |
| Blackstone Alternative I… | 0% | 185 | 2026-06-30 |
| ADVISORS' INNER CIRCLE I… | 0% | 22 | 2026-07-31 |
| SCHOENECK JAMES A (Direc… | — | — | 2025-06-30 |
Logi Sisse Google